Results overview: Found 6 records in 0.02 seconds.
Articles, 6 records found
Articles 6 records found  
1.
9 p, 297.7 KB New clinical trial designs in the era of precision medicine / Garralda, Elena (Universitat Autònoma de Barcelona) ; Dienstmann, Rodrigo (Universitat Autònoma de Barcelona) ; Piris-Giménez, Alejandro (Universitat Autònoma de Barcelona) ; Braña, Irene (Universitat Autònoma de Barcelona) ; Rodon Ahnert, Jordi (Universitat Autònoma de Barcelona) ; Tabernero, Josep (Universitat Autònoma de Barcelona) ; Universitat Autònoma de Barcelona ; VHIO Vall d'Hebron Institut d'Oncologia
Cancer treatment has made significant strides towards the promise of personalized medicine. Recent scientific advances have shown that there are numerous genetic deregulations that are common in multiple cancer types, raising the possibility of developing drugs targeting those deregulations irrespective of the tumour type. [...]
2019 - 10.1002/1878-0261.12465
Molecular Oncology, Vol. 13 (february 2019) , p. 549-557  
2.
8 p, 2.4 MB Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations / Tamborero, David (Institut Hospital del Mar d'Investigacions Mèdiques) ; Rubio-Perez, Carlota (Institut Hospital del Mar d'Investigacions Mèdiques) ; Deu-Pons, Jordi (Institut Hospital del Mar d'Investigacions Mèdiques) ; Schroeder, Michael P. (Charité-Universitätsmedizin (Germany)) ; Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ; Rovira, Ana (Institut Hospital del Mar d'Investigacions Mèdiques) ; Tusquets, Ignasi (Institut Hospital del Mar d'Investigacions Mèdiques) ; Albanell, Joan (Institut Hospital del Mar d'Investigacions Mèdiques) ; Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; de Torres, Carmen (Institut de Recerca Sant Joan de Déu) ; Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ; Gonzalez-Perez, Abel (Institut Hospital del Mar d'Investigacions Mèdiques) ; Lopez-Bigas, Nuria (Institució Catalana de Recerca i Estudis Avançats (ICREA)) ; Universitat Autònoma de Barcelona
While tumor genome sequencing has become widely available in clinical and research settings, the interpretation of tumor somatic variants remains an important bottleneck. Here we present the Cancer Genome Interpreter, a versatile platform that automates the interpretation of newly sequenced cancer genomes, annotating the potential of alterations detected in tumors to act as drivers and their possible effect on treatment response. [...]
2018 - 10.1186/s13073-018-0531-8
Genome Medicine, Vol. 10 (March 2018) , art. 25  
3.
8 p, 357.7 KB Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer / Grasselli, J (Institut Català d'Oncologia) ; Élez Fernández, María Elena (Universitat Autonoma de Barcelona) ; Caratù, G (Vall d'Hebron Institut d'Oncologia) ; Matito, J (Vall d'Hebron Institut d'Oncologia) ; Santos Vivas, Cristina (Institut Català d'Oncologia) ; Macarulla Mercadé, Teresa (Hospital Universitari Vall d'Hebron) ; Vidal, J (Hospital del Mar (Barcelona, Catalunya)) ; Garcia, M (Institut Català d'Oncologia) ; Viéitez, J M (Hospital Universitario de Asturias. Departamento de Oncologia Médica) ; Paéz, D (Institut d'Investigació Biomèdica Sant Pau) ; Falcó, E (Hospital Universitari Son Llatzer. Departament d'Oncologia Mèdica) ; Lopez Lopez, C (Hospital Universitario Marqués de Valdecilla. Departamento de Oncología Médica) ; Aranda, E (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ; Jones, F (Sysmex Inostics, Mundelein, USA) ; Sikri, V (Sysmex Inostics, Mundelein, USA) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Fasani, R (Vall d'Hebron Institut d'Oncologia) ; Tabernero, Josep (Universitat Autonoma de Barcelona) ; Montagut, C (Hospital del Mar (Barcelona, Catalunya)) ; Azuara, D (Institut Català d'Oncologia) ; Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ; Salazar, R (Institut Català d'Oncologia) ; Vivancos, A (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
Circulating tumor DNA (ctDNA) is a potential source for tumor genome analysis. We explored the concordance between the mutational status of RAS in tumor tissue and ctDNA in metastatic colorectal cancer (mCRC) patients to establish eligibility for anti-epidermal growth factor receptor (EGFR) therapy. [...]
2017 - 10.1093/annonc/mdx112
Annals of oncology, Vol. 28 (march 2017) , p. 1294-1301  
4.
10 p, 506.2 KB Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights / Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ; Élez Fernández, María Elena (Hospital Universitari Vall d'Hebron) ; Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia) ; Matos, Ignacio (Vall d'Hebron Institut d'Oncologia) ; Sanz García, Enrique (Vall d'Hebron Institut d'Oncologia) ; Ortiz, Carolina (Vall d'Hebron Institut d'Oncologia) ; Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ; Capdevila, Jaume (Vall d'Hebron Institut d'Oncologia) ; Alsina Maqueda, Maria (Vall d'Hebron Institut d'Oncologia) ; Saurí Nadal, Tamara (Vall d'Hebron Institut d'Oncologia) ; Verdaguer, Helena (Vall d'Hebron Institut d'Oncologia) ; Vilaró, Marta (Vall d'Hebron Institut d'Oncologia) ; Ruiz-Pace, Fiorella (Vall d'Hebron Institut d'Oncologia) ; Viaplana, Cristina (Vall d'Hebron Institut d'Oncologia) ; García Rodríguez, Ariadna (Vall d'Hebron Institut d'Oncologia) ; Landolfi, Stefania (Universitat Autonoma de Barcelona) ; Palmer, Hector G. (Vall d'Hebron Institut d'Oncologia) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ; Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia)
Sequencing of tumors is now routine and guides personalized cancer therapy. Mutant allele fractions (s, or the 'mutation dose') of a driver gene may reveal the genomic structure of tumors and influence response to targeted therapies. [...]
2017 - 10.1002/1878-0261.12099
Molecular Oncology, Vol. 11, Issue 9 (September 2017) , p. 1263-1272  
5.
9 p, 435.9 KB Prediction of overall survival in stage II and III colon cancer beyond TNM system : a retrospective, pooled biomarker study / Dienstmann, Rodrigo. (Hospital Universitari Vall d'Hebron) ; Mason, M. J. (Computational Oncology, Sage Bionetworks, Seattle, USA) ; Sinicrope, F. A. (Mayo Clinic and Mayo Comprehensive Cancer Center, Rochester, USA) ; Phipps, A. I. (Fred Hutchinson Cancer Research Center, Seattle, USA) ; Tejpar, S. (University Hospital Gasthuisberg, Leuven, Belgium) ; Nesbakken, A. (Oslo University Hospital) ; Danielsen, S. A. (Oslo University Hospital) ; Sveen, A. (Oslo University Hospital) ; Buchanan, D. D. (The University of Melbourne) ; Clendenning, M. (The University of Melbourne) ; Rosty, C. (The University of Melbourne) ; Bot, B. (Computational Oncology, Sage Bionetworks, Seattle, USA) ; Alberts, S. R. (Mayo Clinic and Mayo Comprehensive Cancer Center, Rochester, USA) ; Milburn Jessup, J. (National Cancer Institute, National Institute of Health, Rockville, USA) ; Lothe, R. A. (Oslo University Hospital) ; Delorenzi, M. (SIB Swiss Institute Bioinformatics, Lausanne, Switzerland) ; Newcomb, P. A. (Fred Hutchinson Cancer Research Center, Seattle, USA) ; Sargent, D. (Mayo Clinic, Rochester, USA) ; Guinney, J. (Computational Oncology, Sage Bionetworks, Seattle, USA) ; Universitat Autònoma de Barcelona
TNM staging alone does not accurately predict outcome in colon cancer (CC) patients who may be eligible for adjuvant chemotherapy. It is unknown to what extent the molecular markers microsatellite instability (MSI) and mutations in BRAF or KRAS improve prognostic estimation in multivariable models that include detailed clinicopathological annotation. [...]
2017 - 10.1093/annonc/mdx052
Annals of oncology, Vol. 28 (february 2017) , p. 1023-1031  
6.
33 p, 1.9 MB The Consensus Molecular Subtypes of Colorectal Cancer / Guinney, Justin (Sage Bionetworks. Fred Hutchinson Cancer Research Center (USA)) ; Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ; Wang, Xin (City University of Hong Kong. Department of Biomedical Sciences (China)) ; de Reyniès, Aurélien (Ligue Nationale Contre le Cancer (France)) ; Schlicker, Andreas (The Netherlands Cancer Institute (NKI) (Netherlands)) ; Soneson, Charlotte (SIB Swiss Institute of Bioinformatics (Switzerland)) ; Marisa, Laetitia (Ligue Nationale Contre le Cancer (France)) ; Roepman, Paul (Agendia NV (Netherlands)) ; Nyamundanda, Gift (The Institute of Cancer Research (UK)) ; Angelino, Paolo (SIB Swiss Institute of Bioinformatics (Switzerland)) ; Bot, Brian M. (Sage Bionetworks. Fred Hutchinson Cancer Research Center (USA)) ; Morris, Jeffrey S. (The University of Texas M.D. Anderson Cancer Center (USA)) ; Simon, Iris M. (Agendia NV (Netherlands)) ; Gerster, Sarah (SIB Swiss Institute of Bioinformatics (Switzerland)) ; Fessler, Evelyn (University of Amsterdam (Netherlands)) ; de Sousa e Melo, Felipe (University of Amsterdam (Netherlands)) ; Missiaglia, Edoardo (SIB Swiss Institute of Bioinformatics (Switzerland)) ; Ramay, Hena (SIB Swiss Institute of Bioinformatics (Switzerland)) ; Barras, David (SIB Swiss Institute of Bioinformatics (Switzerland)) ; Homicsko, Krisztian (Ecole Polytechnique Federale de Lausanne (Switzerland)) ; Maru, Dipen (The University of Texas M.D. Anderson Cancer Center, Houston (USA)) ; Manyam, Ganiraju C. (The University of Texas M.D. Anderson Cancer Center, Houston (USA)) ; Broom, Bradley (The University of Texas M.D. Anderson Cancer Center, Houston (USA)) ; Boige, Valerie (Gustave Roussy, Villejuif (France)) ; Perez-Villamil, Beatriz (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC)) ; Laderas, Ted (Sage Bionetworks. Fred Hutchinson Cancer Research Center (USA)) ; Salazar, Ramon (Institut d'Investigació Biomèdica de Bellvitge) ; Gray, Joe W. (Oregon Health Sciences University (USA)) ; Hanahan, Douglas (Ecole Polytechnique Federale de Lausanne (Switzerland)) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Bernards, Rene (The Netherlands Cancer Institute (NKI) (Netherlands)) ; Friend, Stephen H. (Sage Bionetworks. Fred Hutchinson Cancer Research Center (USA)) ; Laurent-Puig, Pierre (Universite Paris Descartes (France)) ; Medema, Jan Paul (LEXOR, Center for Experimental Molecular Medicine (CEMM), Academic Medical Center (AMC), University of Amsterdam (Netherlands)) ; Sadanandam, Anguraj (The Institute of Cancer Research (UK)) ; Wessels, Lodewyk (The Netherlands Cancer Institute (NKI) (Netherlands)) ; Delorenzi, Mauro (University of Lausanne (Switzerland)) ; Kopetz, Scott (The University of Texas M.D. Anderson Cancer Center (USA)) ; Vermeulen, Louis (LEXOR, Center for Experimental Molecular Medicine (CEMM), Academic Medical Center (AMC), University of Amsterdam (Netherlands)) ; Tejpar, Sabine (Universitair ziekenhuis Leuven (Belgium)) ; Universitat Autònoma de Barcelona
Colorectal cancer (CRC) is a frequently lethal disease with heterogeneous outcomes and drug responses. To resolve inconsistencies among the reported gene expression-based CRC classifications and facilitate clinical translation, we formed an international consortium dedicated to large-scale data sharing and analytics across expert groups. [...]
2015 - 10.1038/nm.3967
Nature Medicine, Vol. 21, Num. 11 (November 2015) , p. 1350-1356  

See also: similar author names
1 Dienstmann, R
1 Dienstmann, Rodrigo.
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.